KOD News and Press, Kodiak Sciences Inc From 08/08/22

The clinical-stage biotech Kodiak Sciences ( NASDAQ: KOD ) jumped ~15% in the morning hours Monday after the company said its BEACON Phase 3 study for lead asset tedromer met the primary endpoint in patients with macular edema due to retinal vein occlusion. The global trial invo...

Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion PR Newswire Tarcocimab tedromer (KSI-301) dosed every two months met the primary endpoint of non-inferior visual acuity g...

Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy PR Newswire PALO ALTO, Calif. , Aug. 5, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a...

Shares of the clinical-stage eye disease specialist Kodiak Sciences (NASDAQ: KOD) are trending lower on higher-than-normal volume today. Specifically, the biotech's stock price fell by as much as 10% in early morning action on Tuesday, and it was still down by a noteworthy 8.8% as o...

Kodiak Sciences ( NASDAQ: KOD ) is trading lower in the pre-market after Citi downgraded the clinical-stage biotech to Sell from Neutral on Tuesday, citing a failure for the company’s lead candidate KSI-301 in a Phase 3 trial for patients with treatment-naïve retin...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

Shares of Kodiak Sciences (NASDAQ:KOD) have added 15.4% to $9.05 in Tuesday afternoon trading, and if the gains hold, the stock is on track to post an eight positive session in nine. Buoying the stock was KOD's disclosure that its director Baker Bros Advisors LP had purchased about ...

Gainers: Mirati Therapeutics (MRTX) +23%. CymaBay Therapeutics (CBAY) +16%. Veru (VERU) +9%. Kodiak Sciences (KOD) +8%. Allarity Therapeutics (ALLR) +7%. Losers: Verastem (VSTM) -12%. Delcath Systems (DCTH) -11%. Vicarious Surgical (RBOT) -8%. CEL-...

Kodiak Sciences Inc. (NASDAQ:KOD) rose 8.4% as traders circulated a report from Tuesday that biopharma company could become a target for an activist investor after its stock plunged in February. The company is at the tip of Insightia's Vulnerability ranking of companies most li...

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...